Lunit highlights global leadership in cancer AI alongside world health experts with dedicated APEC HLMHE session and WBS 2025 Leaders’ Dialogue
SEOUL, September 19, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced its participation in two major global health gatherings taking place in Seoul this week: the 15th APEC High-Level Meeting on Health and the Economy (APEC HLHME) and the World Bio Summit 2025 (WBS 2025).
Lunit was the only company from Korea invited to lead a dedicated session at APEC HLHME, held September 15-16 at Shilla Hotel Seoul, underscoring its role as a recognized global leader in AI-powered solutions that cover the entire cancer care continuum. The session on September 16 drew an audience of more than 300 policymakers, healthcare leaders, and industry experts.
Questions around this news
What did Lunit present at the APEC High-Level Meeting on Health and the Economy?
Lunit’s September 16 session covered how AI is being used in cancer screening and treatment across APEC member economies. Themes included Korea’s experience with reimbursement approval and clinical adoption, examples of screening initiatives in Southeast Asia, Australia and Singapore, and a future vision for combining imaging, genomic and clinical data in precision medicine.
What APEC-level collaborations did Lunit propose?
The company proposed exploring shared data infrastructure and cross-border training among APEC members. These ideas were presented alongside its discussion of multimodal AI, which combines imaging, genomic and clinical information to support precision medicine. The release describes these as potential areas for collaboration, not as agreements that have already been established.
What is multimodal AI in healthcare?
Multimodal AI uses more than one kind of input, such as medical images, text, laboratory results or genomic information. Combining different data types can help a system identify patterns that may not be apparent from one source alone. Its usefulness depends on the quality, compatibility and appropriate handling of the data.
What does AI pathology mean?
AI pathology applies computational methods, including machine learning, to pathology data such as digitized tissue-slide images. These tools can assist with tasks like identifying patterns or quantifying features in samples. They are used within clinical workflows and do not, by themselves, replace a pathologist’s judgment or responsibility for diagnosis.
During the session, Lunit CEO Brandon Suh, together with senior executives and research leaders, outlined how AI is transforming cancer screening and treatment across APEC member economies. Key themes included:
- Korea’s AI leadership: government reimbursement approval, large-scale clinical adoption at more than 7,000 sites worldwide, and validation by the National Cancer Center.
- Global case studies: how AI is enabling cancer screening in Southeast Asia, Australia, and Singapore, supporting health equity and cost-effective care delivery.
- Future vision: advancing multimodal AI that integrates imaging, genomics, and clinical data to drive precision medicine, and proposing new APEC-level collaborations such as shared data infrastructure and cross-border training.
On September 17, Suh will also serve as moderator of the WBS 2025 Leaders’ Dialogue at the opening ceremony, bringing together senior figures such as Dr. Philippe Duneton, Executive Director of Unitaid, and other international healthcare leaders.
In addition, Lunit is showcasing its AI portfolio throughout both events with an on-site booth, offering demonstrations of its flagship solutions in cancer screening and AI pathology.
“AI is no longer a future vision—it is delivering tangible impact for patients and across healthcare systems today,” said Brandon Suh, CEO of Lunit. “By collaborating with governments, multilateral organizations, and research institutions, we aim to ensure that the benefits of AI-powered cancer care reach every corner of the world.”
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
At a glance
- Company
- Lunit
- Ticker
- KRX: 328130.KQ
- Announcement
- Event
- Location
- Seoul, South Korea
Key figures
- APEC meeting number
- 15th
- APEC meeting dates
- September 15-16
- APEC session audience
- more than 300
- Worldwide sites using Lunit AI
- more than 7,000
People
- Brandon SuhCEO of Lunit
- Philippe DunetonExecutive Director of Unitaid
Products and programs
Earlier from Lunit
- Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
- Lunit Launches Enhanced Lunit INSIGHT CXR4, Secures CE MDR Certification for Expanded AI Capabilities
- Lunit Highlights AI’s Role in Advancing Precision Oncology at ASCO 2025 with 12 Studies
- Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition
- Lunit to Power Germany’s Largest Private Radiology Network with AI Imaging
